Theophylline for Pseudohypoparathyroidism
This study is testing the long-term effects of theophylline ER (a drug taken by mouth) for people with pseudohypoparathyroidism (PHP), a genetic condition affecting growth and hormones. Researchers want to see if theophylline ER can help with weight, how the body handles sugar, and hormone resistance. You can join if you are between 2 and 99 years old and have already finished a previous study on theophylline for PHP. The main goal is to check for any side effects over 24 months. This study is currently unclear about its recruitment status.
- Study design
- This is a single-center, open-label extension study for 34 participants who completed a previous randomized trial. It is a Phase 2 study.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for adverse events for 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Theophylline for Treatment of Pseudohypoparathyroidism
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jaclyn Tamaroff, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Adverse Events24 months
Treatment-emergent adverse events will be compared before and during treatment